Harvard University researchers have developed a system for releasing high doses of drugs in short bursts using ultrasound and self-healing hydrogel. Future therapy could therefore be highly customized and locally delivered at specific times, as opposed to the dominant sustained release paradigm.
Bristol-Myers Squibb claimed bragging rights to the first batch of Phase III data on an immuno-oncology drug that clearly demonstrated an improvement over a standard therapy for overall survival.
InVivo Therapeutics announced June 19 that it is terminating its preclinical hydrogel drug delivery program as the company focuses on its investigational devices for spinal cord injury, the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells.
Pharma companies have taken some heat for their R&D productivity levels as of late, but drug developers and investors may recently have seen some of their faith restored.
Four more drug developers are angling to make Wall Street debuts, lining up to raise a combined $269 million as the market for biotech IPOs has shown renewed signs of life after a tepid spring.
While the world's biopharma players are still working to solve the problem of R&D productivity, they're hardly being stingy in the process. R&D spending across the industry leapt 14% last year, according to EY, a sharp rebound reflecting renewed optimism among drug developers and their investors.
Smartphone technology is picking up steam as a viable diagnostic tool, and a new device that uses the technology could help physicians diagnose and monitor adrenal gland diseases.
What's the future of med tech? Here's a look at some of the most outlandish and perhaps forward-thinking devices in the works.
Antisense specialist Isis Pharmaceuticals has made it all the way to mid-stage trials with ISIS-APOCIII, targeting patients with a rare ailment that leads to dangerously high triglycerides. But that candidate is looking all the more promising in light of two major studies linking its target to reduced rates of heart attack, saddling the biotech with a potential blockbuster.
Gilead Sciences' Sovaldi has broken sales records thanks to its ability to cure hepatitis C with an effective, if costly, 12-week regimen. But rivals believe there's plenty of room in the market for a speedier solution, and Bristol-Myers Squibb plans to use its ex-partner's blockbuster to craft a four-week contender.